Functional characterization of N297A, a murine surrogate for low-Fc binding anti-human CD3 antibodies

Immunological Investigations

Volumn 38, Issue 1, 2009, Pages 76-92

  Chao, Debra T ^a   Ma, Xiaohong ^a   Li, Olga ^a   Park, Hyunjoo ^a   Law, Debbie ^a  

^a PDL BioPharma Inc   (United States)

Author keywords

CD3; Inflammatory bowel disease; Monoclonal antibody; T cells

Indexed keywords

CD3 ANTIBODY; INTERLEUKIN 10; CD3 ANTIGEN; CYTOKINE; FC RECEPTOR; HYBRID PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR; MONOCLONAL ANTIBODY; OVALBUMIN;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL MODEL; ARTICLE; COLITIS; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG ACTIVITY; DRUG MECHANISM; FEMALE; GENETIC VARIABILITY; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN STRUCTURE; T LYMPHOCYTE; WEIGHT REDUCTION; ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; C57BL MOUSE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHO CELL; COLON; CRICETULUS; DRUG EFFECT; GENETICS; HAMSTER; HUMAN; IMMUNOLOGY; LYMPHOCYTE COUNT; METABOLISM; PATHOLOGY; SECRETION; TRANSGENIC MOUSE;

ADOPTIVE TRANSFER; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD3; APOPTOSIS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CHO CELLS; COLITIS; COLON; CRICETINAE; CRICETULUS; CYTOKINES; HUMANS; LYMPHOCYTE COUNT; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; OVALBUMIN; PROTEIN BINDING; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; RECEPTORS, IGG; RECOMBINANT FUSION PROTEINS;

EID: 60749099736     PISSN: 08820139     EISSN: 15324311     Source Type: Journal    
DOI: 10.1080/08820130802608238     Document Type: Article

References (37)

1. Alegre, M.L., Tso, J.Y., Sattar, H.A., Smith, J., Desalle, F., Cole, M., Bluestone, J. A. (1995). An anti-murine CD3 monoclonal antibody with a low affinity for Fc gamma receptors suppresses transplantation responses while minimizing acute toxicity and immunogenicity. J. Immunol. 155:1544-1555.
2. Alegre, M.L., Vandenabeele, P., Depierreux, M., Florquin, S., Deschodt-Lanckman, M., Flamand, V., Moser, M., Leo, O., Urbain, J., Fiers, W., et al. (1991). Cytokine release syndrome induced by the 145-2C11 anti-CD3 monoclonal antibody in mice: prevention by high doses of methylprednisolone. J. Immunol. 146:1184-1191.
3. Bisikirska, B., Colgan, J., Luban, J., Bluestone, J.A., and Herold, K.C. (2005). TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. J. Clin. Invest. 115:2904-2913.
4. Carpenter, P.A., Appelbaum, F.R., Corey, L., Deeg, H.J., Doney, K., Gooley, T., Krueger, J., Martin, P., Pavlovic, S., Sanders, J., et al. (2002). A humanized non-FcRbinding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graftversus-host disease. Blood 99:2712-2719.
5. Carpenter, P.A., Lowder, J., Johnston, L., Frangoul, H., Khoury, H., Parker, P., Jerome, K.R., McCune, J.S., Storer, B., Martin, P., et al. (2005). A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versushost disease. Biol. Blood Marrow Transplant 11:465-471.
6. Carpenter, P.A., Pavlovic, S., Tso, J.Y., Press, O.W., Gooley, T., Yu, X.Z., Anasetti, C. (2000). Non-Fc receptor-binding humanized anti-CD3 antibodies induce apoptosis of activated human T cells. J. Immunol. 165:6205-6213.
7. Cole, M.S., Anasetti, C., Tso, J.Y. (1997). Human IgG2 variants of chimeric anti CD3 are nonmitogenic to T cells. J. Immunol. 159:3613-3621.
8. Cole, M.S., Stellrecht, K.E., Shi, J.D., Homola, M., Hsu, D.H., Anasetti, C., Vasquez, M., Tso, J.Y. (1999). HuM291, a humanized anti-CD3 antibody, is immunosuppressive to T cells while exhibiting reduced mitogenicity in vitro. Transplantation 68:563-571.
9. Davidson, N.J., Leach, M.W., Fort, M.M., Thompson-Snipes, L., Kuhn, R., Muller, W., Berg, D.J., Rennick, D.M. (1996). T helper cell 1-type CD4+ T cells, but not B cells, mediate colitis in interleukin 10-deficient mice. J. Exp. Med. 184:241-251.
10. Endharti, A.T., Rifa, I.M.S., Shi, Z., Fukuoka, Y., Nakahara, Y., Kawamoto, Y., Takeda, K., Isobe, K., Suzuki, H. (2005). Cutting edge: CD8+CD122+ regulatory T cells produce IL-10 to suppress IFN-gamma production and proliferation of CD8+ T cells. J. Immunol. 175:7093-7097.
11. Ferran, C., Sheehan, K., Dy, M., Schreiber, R., Merite, S., Landais, P., Noel, L.H., Grau, G., Bluestone, J., Bach, J.F., et al. (1990). Cytokine-related syndrome following injection of anti-CD3 monoclonal antibody: further evidence for transient in vivo T cell activation. Eur. J. Immunol. 20:509-515.
12. Gangi, E., Vasu, C., Cheatem, D., Prabhakar, B.S. (2005). IL-10-producing CD4+CD25+ regulatory T cells play a critical role in granulocyte-macrophage colony-stimulating factor-induced suppression of experimental autoimmune thyroiditis. J. Immunol. 174:7006-7013.
13. Gleixner, B., Kolb, H. J., Holler, E., Liesenfeld, S., Riedner, C., Hiller, E., Seeber, C., Kempeni, J., Moller, A., Knabe, H., et al. (1991). Treatment of aGVHD with OKT3: clinical outcome and side-effects associated with release of TNF alpha. Bone Marrow Transplant 8:93-98.
14. Herold, K.C., Burton, J.B., Francois, F., Poumian-Ruiz, E., Glandt, M., Bluestone, J.A. (2003). Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala). J. Clin. Invest. 111:409-418.
15. Herold, K.C., Gitelman, S.E., Masharani, U., Hagopian, W., Bisikirska, B., Donaldson, D., Rother, K., Diamond, B., Harlan, D.M., Bluestone, J.A. (2005). A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 54:1763-1769.
16. Hommes, D.W., Plevy, S.E., et al. (2005). Epstein Barr Virus (EBV) replication in severe active, steroid resistant ulcerative colitis (UC) patients treated with visilizumab, an antiCD3 antibody. [Abstract]. Gastroenterology 128, A494.
17. Hsu, D.H., Shi, J.D., Homola, M., Rowell, T.J., Moran, J., Levitt, D., Druilhet, B., Chinn, J., Bullock, C., Klingbeil, C. (1999). A humanized anti-CD3 antibody, HuM291, with low mitogenic activity, mediates complete and reversible T-cell depletion in chimpanzees. Transplantation 68:545-554.
18. Jacobsohn, D.A. (2002). Novel therapeutics for the treatment of graft-versus-host disease. Expert Opin. Investig. Drugs 11:1271-1280.
19. Keymeulen, B., Vandemeulebroucke, E., Ziegler, A. G., Mathieu, C., Kaufman, L., Hale, G., Gorus, F., Goldman, M., Walter, M., Candon, S., et al. (2005). Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N. Engl. J. Med. 352:2598-2608.
20. Li, J., Davis, J., Bracht, M., Carton, J., Armstrong, J., Gao, W., Scallon, B., Fung, R., Emmell, E., Zimmerman, M., et al. (2006). Modulation of antigen-specific T cell response by a non-mitogenic anti-CD3 antibody. Int. Immunopharmacol. 6:880-891.
21. Nimmerjahn, F., Ravetch, J.V. (2007). Antibodies, Fc receptors and cancer. Curr. Opin. Immunol. 19:239-245.
22. Norman, D.J., Vincenti, F., de Mattos, A.M., Barry, J.M., Levitt, D.J., Wedel, N.I., Maia, M., Light, S.E. (2000). Phase I trial of HuM291, a humanized anti-CD3 antibody, in patients receiving renal allografts from living donors. Transplantation 70:1707-1712.
23. Ochi, H., Abraham, M., Ishikawa, H., Frenkel, D., Yang, K., Basso, A.S., Wu, H., Chen, M.L., Gandhi, R., Miller, A., et al. (2006). Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4+ CD25- LAP+ T cells. Nat. Med. 12:627-635.
24. Plevy, S., Salzberg, B., Van Assche, G., Regueiro, M., Hommes, D., Sandborn, W., Hanauer, S., Targan, S., Mayer, L., Mahadevan, U., et al. (2007). A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis. Gastroenterology 133:1414-1422.
25. Ravetch, J.V., Bolland, S. (2001). IgG Fc receptors. Annu. Rev. Immunol. 19:275-290.
26. Sgro, C. (1995). Side-effects of a monoclonal antibody, muromonab CD3/orthoclone OKT3: bibliographic review. Toxicology 105:23-29.
27. Targan, S.S.B., Mayer, L. (2005). A phase I-II study: Multiple dose levels of visilizumab are well tolerated and produce rapid and sustained improvement in ulcerative colitis patients refractory to treatment with IV steroids. Gastroenterology 128:A493.
28. Thistlethwaite, J.R., Jr., Stuart, J.K., Mayes, J.T., Gaber, A.O., Woodle, S., Buckingham, M.R., Stuart, F.P. (1988). Complications and monitoring of OKT3 therapy. Am. J. Kidney Dis. 11:112-119.
29. Trajkovic, V. (2002). Nuvion Protein design labs. Curr. Opin. Investig. Drugs 3:411-414.
30. Vexler, V., Woo, J. (2006). Antibody treatment of ulcerative colitis. Drug Discov. Today Therapeut. Strateg. 3:353.
31. Vossen, A.C., Tibbe, G.J., Kroos, M.J., van de Winkel, J.G., Benner, R., and Savelkoul, H. F. (1995). Fc receptor binding of anti-CD3 monoclonal antibodies is not essential for immunosuppression, but triggers cytokine-related side effects. Eur. J. Immunol. 25:1492-1496.
32. Wesselborg, S., Prufer, U., Wild, M., Schraven, B., Meuer, S.C., Kabelitz, D. (1993). Triggering via the alternative CD2 pathway induces apoptosis in activated human T lymphocytes. Eur. J. Immunol. 23:2707-2710.
33. Woodle, E.S., Bluestone, J.A., Zivin, R.A., Jolliffe, L.K., Auger, J., Xu, D., and Thistlethwaite, J.R. (1998). Humanized, nonmitogenic OKT3 antibody, huOKT3 gamma(Ala-Ala): initial clinical experience. Transplant Proc. 30:1369-1370.
34. Yu, X.Z., Anasetti, C. (2000). Enhancement of susceptibility to Fas-mediated apoptosis of TH1 cells by nonmitogenic anti-CD3epsilon F(ab')2. Transplantation 69, 104-112.
35. Yu, X. Z., Bidwell, S.J., Martin, P.J., Anasetti, C. (2001). Anti-CD3 epsilon F(ab')2 prevents graft-versus-host disease by selectively depleting donor T cells activated by recipient alloantigens. J. Immunol. 166:5835-5839.
36. Yu, X.Z., Levin, S.D., Madrenas, J., Anasetti, C. (2004). Lck is required for activation-induced T cell death after TCR ligation with partial agonists. J. Immunol. 172:1437-1443.
37. Zhang, X., Koldzic, D.N., Izikson, L., Reddy, J., Nazareno, R.F., Sakaguchi, S., Kuchroo, V.K., Weiner, H.L. (2004). IL-10 is involved in the suppression of experimental autoimmune encephalomyelitis by CD25+CD4+ regulatory T cells. Int. Immunol. 16:249-256.